

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Reporting Issuer

Doseology Sciences Inc. (the “Company”)
406 - 460 Doyle Avenue
Kelowna, BC V1Y 0C2

Item 2: Date of Material Change

June 30, 2023.

Item 3: News Release

A news release was issued and disseminated June 30, 2023 and filed on SEDAR at www.sedar.com.

Item 4: Summary of Material Changes

The Company announced the changes to its directors and officers. See item 5 for further details.

Item 5: Full Description of Material Change

The Company announced the appointment of Shawn Balaghi the Interim CEO and Interim CFO of the Company, effective immediately.

Shawn brings over 20 years of experience in the capital markets industry globally, holding key roles in finance, corporate development, and strategic planning. Previously, he has served as the CEO and CFO, and Director for several publicly listed companies and has worked closely with some of the largest independent auditing firms in Canada and the US. Shawn has raised over \$300 Million in funding for several start-ups and has led them to public listings in Canada, the US, and Germany. Shawn has been the President, Director & Co-Founder of RED Bioscience since July 2020, and successfully ran trials at the University of British Columbia on an all-natural formulation preventing and deactivating several variations of the Covid Virus.

The Company also announced that Pratik Patel resigned as the CFO, Interim CEO and a director of the Company and wishes him well in his future endeavors.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

Noe applicable.

Item 8: Executive Officer

For further information, please contact:

Shawn Balaghi, Interim CEO
Investor Relations: investor@doseology.com
General Inquiries: hello@doseology.com
Telephone: 236-349-0064

Item 9: Date of Report

June 30, 2023.